Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain
This program was funded with a lead gift from The Edmond J. Safra Foundation in memory of its founder, Mr. Edmond J. Safra. The Edmond J. Safra Foundation has been one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.
Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundationís Searchable Database of Funded Grants.
As with all MJFF grants, full funding is dependent on the achievement of predetermined, specific milestones and on researchersí agreement to make the results of their work available to the Parkinsonís research community.
Development and Screening of Contrast Agents for In Vivo Imaging of PD
Brian Bacskai, PhD, and Pamela McLean, PhD, Massachusetts General Hospital (Harvard Medical School), Boston, Massachusetts
Utility of the Amyloid Ligand [18F] FDDNP in Human PET Imaging in Parkinsonís Disease
Yvette Bordelon, MD, PhD, University of California, Los Angeles†
18F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies
Franz Hefti, PhD, Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania, and Alan Snow, PhD, ProteoTech, Inc., Seattle, Washington
Generation of Alpha-Synuclein Conformation-specific Aptamers for In Vivo Bioimaging of Alpha-Synuclein Pathology
Poul Henning Jensen, MD, PhD, University of Aarhus, Aarhus, Denmark
A Strategy to Develop a Radiotracer Targeting Alpha-Synuclein
Kenneth Marek, MD, Institute for Neurodegenerative Disorders, New Haven, Connecticut, and Omar El-Agnaf, PhD, United Arab Emirates University
In Vivo SPECT Imaging of Synuclein Aggregation with Morphology-specific Antibody-based Ligands
Michael Sierks, PhD, Arizona State University, Tempe, Arizona